A Phase 3 Study of Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

Full Title

A Phase III Trial of One vs. Two Years of Maintenance Olaparib, with or Without Bevacizumab, in Patients with BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy (NRG-GY036) (CIRB)

Purpose

Researchers are assessing maintenance therapy with olaparib given for 1 or 2 years, with or without bevacizumab, to treat ovarian cancer. The people in this study have stage 3 or 4 ovarian cancer with certain genetic mutations (changes).

Olaparib may stop tumor growth by blocking DNA repair in cancer cells. Bevacizumab blocks the formation of blood vessels that bring oxygen and nutrients to tumors. Olaparib is taken orally (by mouth) and bevacizumab is given intravenously (by vein).

If you join this study, you will be randomly assigned to get one of these treatments:

• Olaparib for 2 years with or without bevacizumab for 1 year.
• Olaparib for 1 year with or without bevacizumab for 1 year.

Contact

For more information or to see if you can join this study, please call Dr. Ying Liu’s office at 646-888-4946.